92 related articles for article (PubMed ID: 12610520)
1. Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.
De Paola F; Ridolfi R; Riccobon A; Flamini E; Barzanti F; Granato AM; Mordenti GL; Medri L; Vitali P; Amadori D
Br J Cancer; 2003 Jan; 88(2):320-6. PubMed ID: 12610520
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.
Mansfield PF; Rosenblum MG; Murray JL; Itoh K
Cancer Immunol Immunother; 1991; 33(4):247-54. PubMed ID: 1829394
[TBL] [Abstract][Full Text] [Related]
3. Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients.
Choi SH; Chung EJ; Whang DY; Lee SS; Jang YS; Kim CW
Cancer Immunol Immunother; 1998 Feb; 45(6):299-305. PubMed ID: 9490199
[TBL] [Abstract][Full Text] [Related]
4. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
Mulder WM; Stukart MJ; Roos M; van Lier RA; Wagstaff J; Scheper RJ; Bloemena E
Cancer Immunol Immunother; 1995 Nov; 41(5):293-301. PubMed ID: 8536275
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
[TBL] [Abstract][Full Text] [Related]
6. On down-regulation of the immune response to metastatic malignant melanoma.
Håkansson A; Gustafsson B; Krysander L; Hjelmqvist B; Rettrup B; Håkansson L
Cancer Immunol Immunother; 1999 Aug; 48(5):253-62. PubMed ID: 10478642
[TBL] [Abstract][Full Text] [Related]
7. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent.
Gruen M; Bommert K; Bargou RC
Cancer Immunol Immunother; 2004 Jul; 53(7):625-32. PubMed ID: 15175907
[TBL] [Abstract][Full Text] [Related]
8. Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non-Hodgkin's lymphomas.
Kudoh S; Wang Q; Hidalgo OF; Rayman P; Tubbs RR; Edinger MG; Kolenko V; Panuto J; Bukowski R; Finke JH
Cancer Immunol Immunother; 1995 Sep; 41(3):175-84. PubMed ID: 7553687
[TBL] [Abstract][Full Text] [Related]
9. Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.
Halapi E; Yamamoto Y; Juhlin C; Jeddi-Tehrani M; Grunewald J; Andersson R; Hising C; Masucci G; Mellstedt H; Kiessling R
Cancer Immunol Immunother; 1993; 36(3):191-7. PubMed ID: 8439980
[TBL] [Abstract][Full Text] [Related]
10. Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.
Nijhuis EW; vd Wiel-van Kemenade E; Figdor CG; van Lier RA
Cancer Immunol Immunother; 1990; 32(4):245-50. PubMed ID: 2175673
[TBL] [Abstract][Full Text] [Related]
11. Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy.
Gratama JW; Zea AH; Bolhuis RL; Ochoa AC
Cancer Immunol Immunother; 1999 Aug; 48(5):263-9. PubMed ID: 10478643
[TBL] [Abstract][Full Text] [Related]
12. Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha.
Baxevanis CN; Spanakos G; Voutsas IF; Gritzapis AD; Tsitsilonis OE; Mamalaki A; Papamichail M
Cancer Immunol Immunother; 1999; 48(2-3):71-84. PubMed ID: 10414460
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism.
Zhu J; Petit PF; Van den Eynde BJ
Cancer Immunol Immunother; 2019 May; 68(5):835-847. PubMed ID: 30406374
[TBL] [Abstract][Full Text] [Related]
14. PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor.
Fujimura A; Nakayama K; Imaizumi A; Kawamoto M; Oyama Y; Ichimiya S; Umebayashi M; Koya N; Morisaki T; Nakagawa T; Onishi H
Cancer Immunol Immunother; 2019 Oct; 68(10):1649-1660. PubMed ID: 31562536
[TBL] [Abstract][Full Text] [Related]
15. Signaling defects in T lymphocytes of patients with malignancy.
Whiteside TL
Cancer Immunol Immunother; 1999 Oct; 48(7):346-52. PubMed ID: 10501846
[TBL] [Abstract][Full Text] [Related]
16. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine.
Berd D; Maguire HC; Mastrangelo MJ; Murphy G
Cancer Immunol Immunother; 1994 Sep; 39(3):141-7. PubMed ID: 7923243
[TBL] [Abstract][Full Text] [Related]
17. Mucin-1-related T cell infiltration in colorectal carcinoma.
Mulder WM; Stukart MJ; de Windt E; Wagstaff J; Scheper RJ; Bloemena E
Cancer Immunol Immunother; 1996 Jul; 42(6):351-6. PubMed ID: 8830738
[TBL] [Abstract][Full Text] [Related]
18. TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism.
Shao Q; Wang L; Yuan M; Jin X; Chen Z; Wu C
Front Immunol; 2021; 12():688961. PubMed ID: 34659197
[TBL] [Abstract][Full Text] [Related]
19. T cell apoptosis in human heart allografts: association with lack of co-stimulation?
Van Hoffen E; Van Wichen DF; Leemans JC; Broekhuizen RA; Bruggink AH; De Boer M; De Jonge N; Kirkels H; Slootweg PJ; Gmelig-Meyling FH; De Weger RA
Am J Pathol; 1998 Dec; 153(6):1813-24. PubMed ID: 9846972
[TBL] [Abstract][Full Text] [Related]
20. T cell receptor-induced activation and apoptosis in cycling human T cells occur throughout the cell cycle.
Karas M; Zaks TZ; Liu JL; LeRoith D
Mol Biol Cell; 1999 Dec; 10(12):4441-50. PubMed ID: 10588669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
